SG11202001397VA - Methods of using dipivefrin - Google Patents

Methods of using dipivefrin

Info

Publication number
SG11202001397VA
SG11202001397VA SG11202001397VA SG11202001397VA SG11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA
Authority
SG
Singapore
Prior art keywords
dipivefrin
methods
Prior art date
Application number
SG11202001397VA
Other languages
English (en)
Inventor
Mingbao Zhang
Original Assignee
Insignis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insignis Therapeutics Inc filed Critical Insignis Therapeutics Inc
Publication of SG11202001397VA publication Critical patent/SG11202001397VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
SG11202001397VA 2017-09-08 2018-09-10 Methods of using dipivefrin SG11202001397VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555854P 2017-09-08 2017-09-08
PCT/US2018/050223 WO2019051387A1 (en) 2017-09-08 2018-09-10 METHODS OF USING DIPIVECHINE

Publications (1)

Publication Number Publication Date
SG11202001397VA true SG11202001397VA (en) 2020-03-30

Family

ID=63686134

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001397VA SG11202001397VA (en) 2017-09-08 2018-09-10 Methods of using dipivefrin

Country Status (14)

Country Link
US (2) US11213496B2 (ja)
EP (1) EP3678648B1 (ja)
JP (2) JP6837700B2 (ja)
KR (1) KR102182559B1 (ja)
CN (1) CN111565716B (ja)
AU (1) AU2018330329B2 (ja)
BR (1) BR112020004586A2 (ja)
CA (1) CA3075271C (ja)
DK (1) DK3678648T3 (ja)
EA (1) EA202090637A1 (ja)
ES (1) ES2954361T3 (ja)
IL (1) IL272851B (ja)
SG (1) SG11202001397VA (ja)
WO (1) WO2019051387A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001397VA (en) 2017-09-08 2020-03-30 Insignis Therapeutics Inc Methods of using dipivefrin
EP3930685A1 (en) * 2019-03-01 2022-01-05 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2023076477A2 (en) 2021-10-27 2023-05-04 Insignis Therapeutics, Inc. Orally disintegrating tablet for epinephrine prodrug formulations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904671A (en) * 1969-04-01 1975-09-09 Sterling Drug Inc Esters of 3-(hydroxy or hydroxymethyl)-4-hydroxyphenyl aminomethyl ketones
FI55988C (fi) * 1971-10-19 1979-11-12 Klinge Co Chem Pharm Fab Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer
US3839584A (en) 1972-08-31 1974-10-01 Interx Research Corp Pharmaceutical compositions containing a novel ester of ((methylamino)methyl)benzyl alcohol and methods of using same
US3809714A (en) * 1972-08-31 1974-05-07 Interx Research Corp Novel ester of ((methylamino)methyl) benzyl alcohol
US3868461A (en) 1972-11-22 1975-02-25 Interx Research Corp Ester of 3,4-dihydroxy-alpha (isopropylamino) methyl benzyl alcohol, composition and anti-asthma use thereof
US4035405A (en) 1976-07-09 1977-07-12 Interx Research Corporation Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives
US4180586A (en) 1977-01-10 1979-12-25 Interx Research Corporation 3,4-Dipivalyl-α-[methylamino)methyl]benzyl alcohol as an adjunct in the treatment of circulatory shock
US4094983A (en) 1977-01-17 1978-06-13 Interx Research Corporation Method for reducing intraocular pressure in warm-blooded animals
US4145441A (en) 1977-11-04 1979-03-20 Interx Research Corporation Sympathomimetic amines exhibiting anti-hemorrhoidal activity
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
PL170554B1 (pl) 1991-12-17 1996-12-31 Fuisz Technologies Ltd Sposób wytwarzania kompozycji przeciwwrzodowej PL PL PL
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5925682A (en) 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
KR20040018394A (ko) * 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
JPWO2003041740A1 (ja) 2001-11-16 2005-03-03 味の素株式会社 腫瘍壊死剤
JP2004231557A (ja) * 2003-01-30 2004-08-19 Katsuyoshi Hori エピネフリン含有抗腫瘍剤
AU2004233744A1 (en) 2003-05-02 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
JP2006193440A (ja) * 2005-01-12 2006-07-27 Medorekkusu:Kk β2刺激剤含有製剤
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2011109340A1 (en) * 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20150164827A1 (en) * 2005-09-09 2015-06-18 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
PL2818184T3 (pl) * 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Kompozycje i sposoby do leczenia plamicy
DE102008007198A1 (de) * 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2015034822A1 (en) 2013-09-03 2015-03-12 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
GB201419257D0 (en) * 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ai治療公司 使用阿吡莫德治療癌症之方法
US20180297966A1 (en) 2015-10-17 2018-10-18 Innovative Anesthetics, Llc Compounds, compositions, and methods of making and using the same
CN106109459A (zh) * 2016-06-22 2016-11-16 丁俣汀 盐酸地匹福林的药物组合物及其在生物医药中的应用
CN110418639B (zh) 2016-11-13 2023-06-02 艾奥诺医药有限公司 肾上腺素前药的舌下或口含给药制剂
SG11202001397VA (en) 2017-09-08 2020-03-30 Insignis Therapeutics Inc Methods of using dipivefrin
EP3930685A1 (en) 2019-03-01 2022-01-05 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations

Also Published As

Publication number Publication date
US11213496B2 (en) 2022-01-04
IL272851A (en) 2020-04-30
CN111565716B (zh) 2023-06-09
EP3678648A1 (en) 2020-07-15
DK3678648T3 (da) 2023-09-11
JP6837700B2 (ja) 2021-03-03
ES2954361T3 (es) 2023-11-21
BR112020004586A2 (pt) 2020-09-08
AU2018330329A1 (en) 2020-03-12
US20220193010A1 (en) 2022-06-23
WO2019051387A1 (en) 2019-03-14
AU2018330329B2 (en) 2020-12-03
KR20200040898A (ko) 2020-04-20
IL272851B (en) 2021-12-01
CA3075271C (en) 2021-10-12
EP3678648B1 (en) 2023-07-26
JP2021063135A (ja) 2021-04-22
KR102182559B1 (ko) 2020-11-24
JP2020528928A (ja) 2020-10-01
CA3075271A1 (en) 2019-03-14
CN111565716A (zh) 2020-08-21
EA202090637A1 (ru) 2020-06-29
US20190076378A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
ZA202006746B (en) Methods of treatment
HK1232140A1 (zh) 微類器官以及製造和使用它們的方法
HK1258062A1 (zh) 給予惡拉戈利的方法
AU364417S (en) Back of the case
HUE057926T2 (hu) Eljárás tiokarbonátok elõállítására
GB2600653B (en) Novel methods
IL268731A (en) New uses of anti-SIRPG antibodies
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL273493A (en) Modified CAR-T
IL272851B (en) Methods for using dipifaprin
SI3254474T1 (sl) Elektroakustični implantat
EP3894768C0 (en) METHOD FOR CRYOHARDENING
ZA201706282B (en) Solid forms of menaquinols
GB201703036D0 (en) Methods
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
HUE057149T2 (hu) Mikromolekula vegyület, eljárás szintézisére és alkalmazására
DK3615520T3 (en) Methods
GB201721386D0 (en) Chrondogy of time-wave
GB201810835D0 (en) Methods of use
GB201719043D0 (en) Methods and compounds
GB201721724D0 (en) Gametogenesis
GB201715203D0 (en) Novel methods
GB201715089D0 (en) Novel methods
PT3471835T (pt) Utilização de extratos de deschampsia antarctica para combater danos na barreira cutânea humana provocados por agressões ambientais